Related references
Note: Only part of the references are listed.Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji K. Kumar et al.
LANCET ONCOLOGY (2020)
Deciphering the chronology of copy number alterations in Multiple Myeloma
Anil Aktas Samur et al.
BLOOD CANCER JOURNAL (2019)
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A. Walker et al.
BLOOD (2018)
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Shih-Feng Cho et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The cellular origin and malignant transformation of Waldenstrom macroglobulinemia
Bruno Paiva et al.
BLOOD (2015)
Genetics of multiple myeloma: another heterogeneity level?
Jill Corre et al.
BLOOD (2015)
MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The generation of antibody-secreting plasma cells
Stephen L. Nutt et al.
NATURE REVIEWS IMMUNOLOGY (2015)
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R. Hunter et al.
BLOOD (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance
Marzia Varettoni et al.
BLOOD (2013)
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells
Brian A. Walker et al.
BLOOD (2013)
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities
Esteban Braggio et al.
MODERN PATHOLOGY (2012)
IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia
Steven R. Schuster et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Pathophysiology of Waldenstrom's macroglobulinemia
Marvin J. Stone et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
CD27 in Defining Memory B-Cell Origins in Waldenstrom's Macroglobulinemia
Surinder S. Sahota et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Transcriptional networks in developing and mature B cells
P Matthias et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Regulation of plasma-cell development
M Shapiro-Shelef et al.
NATURE REVIEWS IMMUNOLOGY (2005)
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
N Robillard et al.
BLOOD (2003)
Share Paper
